OBJECTIVES: Radiologically small-sized adenocarcinomas are special entities of lung cancer, as their radiological and pathological invasiveness determines the surgical procedures applied; however, the clinicopathological features of small-sized lung adenocarcinoma adjoining cystic airspaces (Ca-ADJ) have yet to be fully clarified. The aim of this study was to elucidate the clinicopathological characteristics, including the programmed death ligand 1 (PD-L1) expression, in patients with Ca-ADJ < _3.0 cm.
INTRODUCTION
Lung cancer is the leading cause of cancer-related deaths worldwide, and its prognosis remains poor [1] . Recent advances in molecular-targeted agents and immune checkpoint inhibitors have prolonged the survival of patients with lung cancer; however, surgical resection remains the only curative treatment option. Stage I non-small-cell lung cancer can be curatively treated by lobar resection combined with nodal dissection [2] . Radiologically smallsized adenocarcinomas often exhibit ground-glass opacity mixed with some extent of consolidation, which indicates a pathologically invasive property [3] . According to a prospective trial conducted in Japan, a consolidation/tumour (C/T) ratio of < _0.25 in small nodules of < _2.0 cm in diameter on thin-section computed tomography (CT) was defined as radiological non-invasive lung adenocarcinoma, as such nodules correspond to pathologically non-invasive adenocarcinomas with extremely high specificity [3] . Based on this evidence, several prospective studies have been conducted to investigate the significance of limited resection in patients with small lung adenocarcinomas with some degree of consolidation [4, 5] . Although waiting for the results of such studies would be best approach, limited resection is already being performed in patients with radiologically non-invasive adenocarcinoma. Therefore, calculating the radiological invasiveness is extremely important for determining the most appropriate surgical procedures to perform, such as lobectomy or limited resection. Several reports have described the potential association of emphysematous bullae (EB) with an increased risk of lung cancer [6] [7] [8] [9] [10] [11] [12] . Six-and 32-fold greater risks were reported in lung cancer patients with EB than in those without in 2 studies [9, 11] . In addition, a recent report by Iwama et al. [8] showed that, among 339 patients with lung cancer, EB was identified in 45 (13.3%) patients, and most of the cancers in smokers with EB presented as cancer adjoining EB [lung adenocarcinoma adjoining cystic airspaces (Ca-ADJ); 39 of 45 (86.7%) patients]. Furthermore, our recent data suggested that lung cancer associated with EB, specifically Ca-ADJ, expressed programmed death ligand 1 (PD-L1) more frequently than those not associated with EB [13] . Thus, the clinical and the biological significances of lung cancer associated with EB and Ca-ADJ have been gradually elucidated; however, the characteristics of patients with small-sized Ca-ADJ have yet to be clarified.
In this study, we evaluated the clinicopathological characteristics, including the PD-L1 expression, in patients with Ca-ADJ < _3.0 cm.
METHODS

Study patients
Two hundred and eighty-three patients with lung adenocarcinoma radiologically < _3.0 cm without lymph node or distant metastases on preoperative high-resolution CT who underwent surgery at the Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, between January 2003 and December 2012 were included in this study. Tissue specimens from the enrolled patients were retrieved from the registry of the Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University. The clinicopathological features, including age at surgery, gender, smoking history, forced expiratory volume in 1 s, tumour differentiation (7th edition of the General Rule for Clinical and Pathological Record of Lung Cancer, Japan), pathological tumour-node-metastasis (TNM) stage (7th edition of the lung cancer staging system), pleural or lymphovascular invasion, histological subtype (World Health Organization Classification 2015), surgical procedure, adjuvant chemotherapy and epidermal growth factor receptor (EGFR) mutation status, were examined. EGFR status was determined in tumour tissue using the peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp method (Mitsubishi Chemical Medience, Tokyo, Japan) in 193 specimens [14] . Briefly, the systematic dissection of the hilar and mediastinal lymph nodes was performed at the same time as pulmonary lobectomy. After surgery, routine check-ups, including a physical examination, blood tests (including serum tumour markers) and chest X-ray, were performed at 3-month intervals for the first 3 years and at 6-month intervals thereafter. CT was performed twice a year for the first 3 years and then at least annually thereafter. Clinical information and follow-up data were obtained from the medical records. This study was approved by our institutional review board.
Chest computed tomography
Chest CT was performed in the supine position during inspiratory breath-hold using various multidetector row scanners: Aquilion 4 (Toshiba), Aquilion 64 (Toshiba), Aquilion ONE (Toshiba), Aquilion ONE Vision (Toshiba), SOMATOM Plus4 Volume Zoom (Siemens), Briliance CT (Phillips) and Briliance iCT (Phillips). Imaging parameters for thin-section CT were as follows: tube voltage, 120 kVp; tube current, 100-500 mA; scan field of view, 320-360 mm and slice thickness, 2 mm. A real exposure control (Toshiba) or an automatic exposure control (Siemens and Phillips) was added in each study. All of the CT data sets were transferred to a Picture Archiving and Communication System (PACS), which was accessible at the workstations (Volume Analyzer, SYNAPSE-VINCENT, Fujifilm, Tokyo, Japan) with a specialized application for the lungs. The diameter of consolidation in each tumour (C) and the diameter of the whole tumour including ground-glass opacity (T) were measured manually with axial 2D CT data on a 2-mm slice section; the C/T ratio was then calculated. G.T., M.K. and K.T. evaluated all of the CT images, and any discrepancies in their evaluations were resolved by averaging.
Positron emission tomography/computed tomography 18 F-fluorodeoxyglucose positron emission tomography/computed tomography scanning was performed using various scanners: SECAT EXACT HR + (Siemens), Biograph mCT (Siemens) and Discovery STElite16 (GE). The maximum standardized uptake value (SUVmax) of the tumour was evaluated, and statistical analysis was performed.
Immunohistochemical analyses
Immunohistochemistry was performed in 283 patients with surgically resected primary lung adenocarcinomas using formalinfixed tissue sections as described previously [15] . Sections were cut (4 lm thickness), dewaxed with xylene and rehydrated through a graded series of ethanol baths. After the inhibition of endogenous peroxidase activity for 30 min with 3% hydrogen peroxide in methanol, the sections were pretreated with Target Retrieval Solution (Dako, Glostrup, Denmark) in a decloaking chamber at 110 C for 15 min and then incubated with monoclonal antibodies at 4 C overnight. The immune complex was detected with a DAKO EnVision Detection System (Dako). The sections were finally reacted in 3, 3 0 -diaminobenzidine, counterstained with haematoxylin and mounted. The primary antibody was an anti-human PD-L1 rabbit monoclonal antibody (clone SP142, dilution 1:100; Spring Bioscience, Ventana, Tucson, AZ, USA). Carcinoma cells showing membranous staining for PD-L1 were evaluated as positive cells. The proportion of PD-L1-positive cells was estimated as the percentage of total carcinoma cells. They were evaluated independently by 3 investigators (G.T., K.T. and M.K.). If the independent assessments did not agree, the slides were reviewed together to achieve a consensus. The consensus judgements were adopted as the final results. We set the cut-off values at 5% as described previously [16] . Sections from human placentas for PD-L1 were used as positive controls.
Statistical analyses
The clinicopathological characteristics were summarized using descriptive statistics, and all comparisons between Ca-ADJ+ and Ca-ADJ-were analysed using the Fisher's exact test. Difference between Ca-ADJ+ and Ca-ADJ-for the SUVmax on preoperative 18 F-fluorodeoxyglucose positron emission tomography/computed tomography was evaluated using the Student's t-test. The overall survival (OS) was defined as the time from the initial surgery until death from any cause, whereas the disease-free survival (DFS) was defined as the time from the initial surgery until recurrence. Patients without an event were censored for these end-points at the time of their last follow-up examination. The survival curves were estimated using the Kaplan-Meier method and were compared using the log-rank test. The Cox proportional hazards model or logistic regression model was used to explore prognostic factors for DFS, OS and PD-L1 expression. All of the statistical analyses were conducted using the JMP version 12 software program (SAS Institute, Cary, NC, USA). The P-values of <0.05 were considered to indicate statistically significant differences. Table 1 lists the characteristics of the patients included in this translational study. Among the 283 patients, 31 (11.0%) patients were reported to have Ca-ADJ, whereas the remaining 252 (89.0%) patients were non-Ca-ADJ. One hundred and forty-nine (52.7%) patients were female, and 134 (47.3%) patients were male. One hundred and thirty-seven (48.4%) patients had a history of smoking, and the forced expiratory volume in 1 s was <70% in 68 (24.1%) patients. One hundred ninety-eight (70.0%) patients underwent lobectomy, bilobectomy or pneumonectomy, whereas 56 (19.8%) patients and 29 (10.2%) patients underwent wedge resection and segmentectomy, respectively. Among the 283 patients, the frequencies of C/T ratios of 0, 0.1-0.25, 0.26-0.5 and > _0.51 were 13.4%, 6.7%, 13.4% and 66.5%, respectively (P = 0.007). The numbers of patients with pathological Stages I, II and III disease were 234 (82.7%), 24 (8.5%) and 25 (8.8%), respectively. Pleural, lymphatic and vessel invasions were observed in 47 (16.6%), 29 (10.2%) and 63 (22.3%) patients, respectively. Thirty-eight (13.4%) patients exhibited pathological non-invasive subtypes, and 43 (15.2%) of 283 patients received adjuvant chemotherapy. Eighty-seven (50.3%) of 173 patients with information on their EGFR mutation status available were positive for EGFR mutations.
RESULTS
Clinicopathological characteristics of the patients
The Fisher's exact test showed that Ca-ADJ was significantly associated with male gender (P < 0.001), a history of smoking (P < 0.001), a high C/T ratio (P = 0.026), advanced pathological stage (P < 0.001), the presence of pleural (P < 0.001) and vessel invasion (P < 0.001), histological invasive subtypes (P < 0.001), the administration of adjuvant chemotherapy (P = 0.013) and wild-type EGFR status (P = 0.001). In addition, when analyses were confined to adenocarcinomas < _2.0 cm in diameter on high-resolution CT, similar results were obtained, as presented in Table 2 .
Association between lung adenocarcinoma adjoining cystic airspaces and the metabolic activity and programmed death ligand 1 expression in patients with lung cancer
Patients with Ca-ADJ exhibited significantly higher maximum standardized uptake than those with non-Ca-ADJ (mean value: 8.4 vs 4.1, P < 0.001; Table 3 , Fig. 1) . Furthermore, Ca-ADJ was significantly associated with the PD-L1 expression: 28 (11.1%) and 17 (54.8%) in 252 non-Ca-ADJ and 31 Ca-ADJ were positive for PD-L1 expression, respectively (P < 0.001; Table 4 ). The multivariate analysis revealed that Ca-ADJ (P = 0.040) as well as the presence of vascular invasion (P = 0.033) and EGFR mutations (P = 0.011) were independent predictors of PD-L1 (Supplementary Material, Table  S3 ). Only PD-L1 was found to be an independent predictor of Ca-ADJ (P = 0.025), whereas there was a non-significant trend between Ca-ADJ and a history of smoking (P = 0.068; Supplementary Material, Table S4 ).
Survival analyses according to lung adenocarcinoma adjoining cystic airspaces
The log-rank test showed that patients with Ca-ADJ had significantly shorter DFS than those with non-Ca-ADJ (P = 0.004), whereas there was no significant difference in the OS of the patients with and without Ca-ADJ (P = 0.124; Fig. 2 ). The 5-year DFS and OS were 76.5% and 90.3% in Ca-ADJ patients and 63.8% and 78.4% in non-Ca-ADJ patients, respectively. A multivariate analysis showed that Ca-ADJ was not an independent prognostic factor for the DFS, although the pathological stage, lymphatic invasion and histological subtype were independent prognostic factors for the DFS (Supplementary Material, Table S1 ). In addition, a multivariate analysis showed that Ca-ADJ was not an independent prognostic factor for the OS either, although age, lymphatic invasion and vessel invasion were independent prognostic factors for the OS (Supplementary Material, Table S2 ).
Comments
Radiologically small-sized adenocarcinomas often contain components of ground-glass opacity mixed with some degree of consolidation, and a high C/T ratio was shown to correspond to pathological invasiveness [3] . A prospective radiological study conducted by the Japan Clinical Oncology Group (JCOG0201) defined a C/T ratio of < _0.25 in small nodules of < _2.0 cm in diameter on thin-section CT as radiologically non-invasive lung adenocarcinoma, as such nodules correspond to pathologically non-invasive adenocarcinomas with a specificity as high as 98.7% [3] . Based on this evidence, the JCOG has conducted several prospective studies to investigate the significance of limited resection in patients with small lung adenocarcinomas with some degree AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; Ca-ADJ: adenocarcinoma adjoining cystic airspaces; C/T: consolidation/tumour; EGFR: epidermal growth factor receptor; FEV1.0: forced expiratory volume in 1 s; HRCT: high-resolution computed tomography; MIA: minimally invasive adenocarcinoma. of consolidation [4, 5] . Although waiting for the results of such studies would be the best approach, patients with radiologically non-invasive adenocarcinoma often undergo limited resection, such as wedge resection and segmentectomy, in clinical settings. However, evidence is insufficient for the appropriate management of patients with small-sized Ca-ADJ; we therefore attempted to elucidate the clinicopathological characteristics of Ca-ADJ. To our knowledge, there have been no reports describing the detailed clinicopathological characteristics of Ca-ADJ, including the EGFR mutation status and PD-L1 expression, as in this study. This study showed that Ca-ADJ was significantly associated with radiological and pathological invasiveness, such as a higher Figure 2 : The Kaplan-Meier curves according to Ca-ADJ. The log-rank test showed that (A) disease-free survival was significantly worse in patients with Ca-ADJ than in those without (P = 0.004), whereas there was no significant difference in overall survival (B) between those with and without Ca-ADJ (P = 0.124). Ca-ADJ: lung adenocarcinoma adjoining cystic airspaces. Ca-ADJ: adenocarcinoma adjoining cystic airspaces; PD-L1: programmed death ligand 1.
C/T ratio, advanced pathological stage, the presence of pleural and vessel invasion and histological invasive subtypes, which was also confirmed when our analysis was limited to adenocarcinomas < _2.0 cm in diameter. The pathologically invasive traits of Ca-ADJ as shown in this study are in line with the report by Hanaoka et al. [7] . Furthermore, Ca-ADJ was shown to be metabolically active, which partially supports its invasive nature. In addition, patients with Ca-ADJ exhibited a significantly shorter DFS than those with non-Ca-ADJ (P = 0.004). Given these findings, limited resection may not be applicable for patients with Ca-ADJ, even if limited to lesions < _2.0 cm in diameter, although these findings should be confirmed by future studies. Intriguingly, the results showed a close, significant relationship between Ca-ADJ and the PD-L1 expression: 28 (11.1%) and 17 (54.8%) of 252 non-Ca-ADJ and 31 Ca-ADJ patients, respectively, were positive for PD-L1 expression (P < 0.001). Present and previous studies have shown that the PD-L1 expression in lung cancer was strongly associated with a history of smoking [15, 17] . These results are partially supported by the finding that Ca-ADJ was significantly associated with wild-type EGFR (P = 0.001), which was also demonstrated by Iwama et al. [8] . Given that bullae formation is closely related to tobacco smoking, it is possible that the PD-L1 protein expression may contribute to lung carcinogenesis, which should be clarified in future preclinical and clinical studies.
The reasons why the PD-L1 protein was expressed at such high frequency in Ca-ADJ remain unclear. One possible reason is the regulation of the PD-L1 expression through interferon gamma from inflammatory cells in the areas of EB. In chronic obstructive pulmonary disease, such as pulmonary emphysema, inflammation is known to persist, regardless of the cessation of cigarette smoking [18] . Such inflammation might induce the expression of PD-L1 via interferon gamma, as interferon gamma is known to mediate the expression of PD-L1 [19, 20] .
In addition to the clinical role of PD-L1 as a prognostic predictor in several types of cancer, including lung cancer [15, 21] , PD-L1 expression serves as a biomarker for predicting the response to immune checkpoint inhibitors, such as nivolumab and pembrolizumab [22] [23] [24] . Although surgical resection is still the treatment option with the highest cure rate for patients with early-stage non-small-cell lung cancer, surgery alone is not sufficient to prolong the DFS and the OS in a large portion of resected patients, indicating a need for optimal neoadjuvant and/ or adjuvant therapy. Although uracil-tegafur and cisplatin plus vinorelbine are administered for pathological Stage I and Stage II/IIIA disease, respectively [25, 26] , the significance of adjuvant treatment with immune checkpoint inhibitors, such as nivolumab and pembrolizumab, has yet to be clarified, although these agents are expected to prolong the DFS and the OS in lung cancer patients when used as induction and/or adjuvant therapy [27] . Given the finding in this study that patients with Ca-ADJ exhibited PD-L1 expression more frequently than those with non-Ca-ADJ, Ca-ADJ patients might be successfully treated with adjuvant therapy with PD-1 or PD-L1 inhibitors. This should be clarified in ongoing and future prospective trials.
Limitations
Several limitations associated with this study warrant mention, including its retrospective nature, single-institutional design and limited sample size focusing on adenocarcinoma histology. In addition, only 1 antibody (SP142) and 1 cut-off value (5%) were used for the evaluation of the PD-L1 protein expression. The Blueprint Working Group demonstrated the heterogeneity of the PD-L1-positive rate between 4 antibodies (SP142, 28-8, 22C3 and SP263) [28] . Similarly, our data revealed inconsistency in the PD-L1 expression between different antibodies in small-cell lung cancer [29] . Given these limitations, large-scale, multi-institutional, prospective studies using multiple antibodies and cut-off values are warranted.
CONCLUSION
In conclusion, this study showed that patients with radiologically small-sized Ca-ADJ exhibited radiologically and pathologically invasive features and that Ca-ADJ was significantly associated with the PD-L1 expression.
